Liposomal encapsulated anthracyclines: new therapeutic horizons
- 1 March 2001
- journal article
- review article
- Published by Springer Nature in Current Oncology Reports
- Vol. 3 (2), 156-162
- https://doi.org/10.1007/s11912-001-0016-5
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- Increased intracellular drug accumulation and complete chemosensitization achieved in multidrug-resistant solid tumors by co-administering valspodar(PSC 833) with sterically stabilized liposomal doxorubicinInternational Journal of Cancer, 1999
- Doxorubicin Encapsulated in Liposomes Containing Surface‐Bound Polyethylene Glycol: Pharmacokinetics, Tumor Localization, and Safety in Patients with AIDS‐Related Kaposi's SarcomaThe Journal of Clinical Pharmacology, 1996
- Phase I and pharmacologie study of liposomal daunorubicin (DaunoXome)Investigational New Drugs, 1994
- Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicityCancer Treatment Reviews, 1993
- Antitumor Activity of Liposome-Encapsulated Doxorubicin in Advanced Breast Cancer: Phase II StudyJNCI Journal of the National Cancer Institute, 1990
- Alternative Methods of Drug DeliveryPublished by Springer Nature ,1982
- Pharmacologic and Therapeutic Characteristics of Anthracycline Liposome PreparationPublished by Springer Nature ,1982
- Second-Generation AnthracyclinesPublished by Springer Nature ,1982
- Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease.Clinical evaluation with special reference to childhood leukemiaCancer, 1967
- ‘Daunomycin’, a New Antibiotic of the Rhodomycin GroupNature, 1964